We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for cenegermin (recombinant human nerve growth factor) (JACE Pharma Pty Ltd)
Active ingredients
cenegermin (recombinant human nerve growth factor)
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults
Therapeutic area
Ophthalmology